By gaining the FDA's blessing for the first clinical trial of an embryonic stem cell (ESC)-based therapy, Geron Corp. injected a newfound enthusiasm for the space, helped, in part, by the anticipated loosening of federal funding restrictions by the newly sworn in Obama administration. Read More
